CDK4 and breast cancer: Several clinical studies that were carried out during the last years led to the approval by the Federal Drug Administration and European Medicines Agency of three selective CDK4/6 inhibitors, Palbociclib, Ribociclib and Abemaciclib, for the treatment of advanced metastatic HR+/HER2- breast cancer.